Analyst
JPMorgan
Analyst
Barclays
Equibles does not estimate personal net worth.
James Gordon is recorded as Analyst at JPMorgan and Analyst at Barclays. James Gordon has spoken on 14 earnings calls and 1 other investor event across 8 companies, most recently for Galderma Group AG on October 22, 2026. Those appearances were for Genmab A/S (GMAB), Galderma Group AG (GALDY), Novo Nordisk A S (NVO), Astrazeneca PLC (AZN), HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY and 3 other companies. The companies whose calls James Gordon spoke on are classified in the Healthcare sector.
“A question and a couple of clarifications, please. One question was on PETO. So the first line trial is now going to report before the refractory trial, presumably because the first line has an OR primary with interim OS, whereas the refractory trial is more mature OS.”
“Also, on the road for this CRL, so you've had a little bit more time to digest it. How does it compare to the first CRL in terms of is it as many things to do or is it more benign?”
JPMorgan
Analyst
Source not stated
Barclays
Analyst
Source not stated
GMAB
Biotechnology · Healthcare
GALDY
Drug Manufacturers - Specialty & Generic · Healthcare
NVO
Drug Manufacturers - General · Healthcare
AZN
Drug Manufacturers - General · Healthcare
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
Drug Manufacturers - Specialty & Generic · Healthcare
NVS
Drug Manufacturers - General · Healthcare
ARGX
Biotechnology · Healthcare
Roche Holding AG
Drug Manufacturers - General · Healthcare
Interim results H1 2026
HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY
Roche has published its Full Year Results for 2025 prior to the opening of the Swiss Stock Exchange on Thursday, 29 January 2026.
Roche Holding AG
